T. Rowe Price Associates’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-8,360
| Closed | -$65K | – | 3027 |
|
|
2024
Q3 | $65K | Hold |
8,360
| – | – | ﹤0.01% | 2893 |
|
|
2024
Q2 | $51K | Buy |
8,360
+3,593
| +75% | +$21.9K | ﹤0.01% | 2852 |
|
|
2024
Q1 | $43K | Buy |
4,767
+132
| +3% | +$1.19K | ﹤0.01% | 2890 |
|
|
2023
Q4 | $44K | Hold |
4,635
| – | – | ﹤0.01% | 2826 |
|
|
2023
Q3 | $56K | Buy |
4,635
+1,870
| +68% | +$22.6K | ﹤0.01% | 2760 |
|
|
2023
Q2 | $68K | Buy |
2,765
+201
| +8% | +$4.94K | ﹤0.01% | 2760 |
|
|
2023
Q1 | $81K | Buy |
2,564
+98
| +4% | +$3.1K | ﹤0.01% | 2722 |
|
|
2022
Q4 | $174K | Buy |
2,466
+70
| +3% | +$4.94K | ﹤0.01% | 2574 |
|
|
2022
Q3 | $207K | Buy |
2,396
+862
| +56% | +$74.5K | ﹤0.01% | 2529 |
|
|
2022
Q2 | $127K | Buy |
+1,534
| New | +$127K | ﹤0.01% | 2706 |
|